Li Juan Liu

20190241551, Aug 8, 2019

Jun 21, 2017

16/312206

- Bethesda MD, US
- North Carolina NC, US
Kyle Ryan BRIMACOMBE - Bethesda MD, US
Mindy Irene Emily DAVIS - Rockville MD, US
Yuhong FANG - Rockville MD, US
Matthew HALL - Rockville MD, US
Ajit JADHAV - Chantilly VA, US
Li LIU - Germantown MD, US
Natalia MARTINEZ - Rockville MD, US
Andrew Louis MCIVER - Durham NC, US
Rajan PRAGANI - Gaithersburg MD, US
Jason Matthew ROHDE - Poolesville MD, US
Anton SIMEONOV - Bethesda MD, US
Wei ZHAO - Rockville MD, US
Min SHEN - Boyds MD, US

C07D 417/14
C07D 487/08
A61K 31/4995
A61K 31/496

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; Rand Rare each independently a halogen, CN, CF, CHF, CHF, a C-C10alkyl group, a C1-Calkoxy group, a di(C-Calkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

20190071434, Mar 7, 2019

Dec 22, 2015

15/538570

- Bethesda MD, US
- Chapel Hill NC, US
Rajan Pragani - Gaithersburg MD, US
LI Liu - Germantown MD, US
Mindy Irene Emily Davis - Rockville MD, US
Kyle Ryan Brimacombe - Bethesda MD, US
Min Shen - Boyds MD, US
Anton Simeonov - Bethesda MD, US
Daniel Jason Urban - Rockville MD, US
Ajit Jadhav - Chantilly VA, US
Xiaodong Wang - Chapel Hill NC, US
Andrew Louis McIver - Durham NC, US

C07D 417/04
A61K 31/4709
A61K 31/496
A61K 31/4439
C07D 417/14
A61K 31/4375
C07D 471/04
A61K 31/435
A61K 31/4545
A61K 31/551
A61K 31/437
A61K 31/5377
A61K 31/4704
C07D 215/54
C07D 401/04
A61K 31/506
C07D 215/227
C07D 491/048
C07D 213/82
C07D 487/10
C07D 451/02
A61K 31/46
A61K 31/499
C07D 413/14

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X, X, Rand Rare disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

20190030031, Jan 31, 2019

Oct 5, 2018

16/152735

- Bethesda MD, US
- Salt Lake City UT, US
Li Liu - Germantown MD, US
Cordelle D. Tanega - Rockville MD, US
Min Shen - Boyds MD, US
Kent Lai - Salt Lake City UT, US
Manshu Tang - Salt Lake City UT, US
Douglas S. Auld - Beverly MA, US

A61K 31/517
C07D 491/107
C07D 403/12
C07D 413/14
C07D 493/10
A61K 31/506
C07D 413/12
C07D 417/14
A61K 31/527
C07D 495/10

Disclosed are inhibitors of human galactokinase of formula (I) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).

20170267739, Sep 21, 2017

Nov 25, 2014

15/039384

- Bethesda MD, US
Li Liu - Bethesda MD, US
Bhavik Patel - Bethesda MD, US
Steven A. Rosenberg - Potomac MD, US
Richard A. Morgan - Cambridge MA, US
Mustafa H. Ghanem - Brooklyn NY, US
Barna Dey - Germantown MD, US

Health and Human Services - Bethesda MD

C07K 14/73
C07K 16/10

The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.

20170035760, Feb 9, 2017

Aug 11, 2016

15/234934

- BETHESDA MD, US
- SALT LAKE CITY UT, US
Li Liu - Germantown MD, US
Cordelle D. Tanega - Rockville MD, US
Min Shen - Boyds MD, US
Kent Lai - Salt Lake City UT, US
Manshu Tang - Salt Lake City UT, US
Douglas S. Auld - Beverly MA, US

A61K 31/517
A61K 31/506
A61K 31/527

Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).

20140288100, Sep 25, 2014

Sep 23, 2011

14/346400

Matthew B. Boxer - New Market MD, US
Martin J. Walsh - Carmel IN, US
Li Liu - Germantown MD, US
Cordelle D. Tanega - Virginia Beach VA, US
Min Shen - Boyds MD, US
Kent Lai - Salt Lake City UT, US
Manshu Tang - Salt Lake City UT, US
Douglas S. Auld - Beverly MA, US

University of Utah Research Foundation - Salt Lake City UT
The United States of American, as Represented by the Decretary, Department of Health and Human - Bethesda MD

C07D 495/10
C07D 417/14
C07D 403/12
C07D 413/14
C07D 413/12
C07D 491/107

51426621, 544231, 5142662, 51426624, 51426623, 544253, 544331, 514275, 435375

Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I)